264 related articles for article (PubMed ID: 37466500)
1. Ferroptosis and Necroptosis Produced Autologous Tumor Cell Lysates Co-Delivering with Combined Immnoadjuvants as Personalized
Shi W; Feng W; Li S; Cui Y; Liu S; Jiang H; Liu Y; Zhang H
ACS Nano; 2023 Aug; 17(15):14475-14493. PubMed ID: 37466500
[TBL] [Abstract][Full Text] [Related]
2. Fe(III)-Shikonin supramolecular nanomedicines as immunogenic cell death stimulants and multifunctional immunoadjuvants for tumor vaccination.
Feng W; Shi W; Cui Y; Xu J; Liu S; Gao H; Zhu S; Liu Y; Zhang H
Theranostics; 2023; 13(15):5266-5289. PubMed ID: 37908730
[TBL] [Abstract][Full Text] [Related]
3. Fe(III)-Shikonin Supramolecular Nanomedicine for Combined Therapy of Tumor via Ferroptosis and Necroptosis.
Feng W; Shi W; Liu S; Liu H; Liu Y; Ge P; Zhang H
Adv Healthc Mater; 2022 Jan; 11(2):e2101926. PubMed ID: 34738742
[TBL] [Abstract][Full Text] [Related]
4. Fused Cytomembrane-Camouflaged Nanoparticles for Tumor-Specific Immunotherapy.
Ji P; Deng XC; Jin XK; Zhang SM; Wang JW; Feng J; Chen WH; Zhang XZ
Adv Healthc Mater; 2023 Sep; 12(23):e2300323. PubMed ID: 37212324
[TBL] [Abstract][Full Text] [Related]
5. CpG-Based Nanovaccines for Cancer Immunotherapy.
Chen W; Jiang M; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
Int J Nanomedicine; 2021; 16():5281-5299. PubMed ID: 34385817
[TBL] [Abstract][Full Text] [Related]
6. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-L1 DNAzyme Loaded Photothermal Mn
Liu P; Shi X; Peng Y; Hu J; Ding J; Zhou W
Adv Healthc Mater; 2022 Apr; 11(8):e2102315. PubMed ID: 34841741
[TBL] [Abstract][Full Text] [Related]
8. Rough Nanovaccines Boost Antitumor Immunity Through the Enhancement of Vaccination Cascade and Immunogenic Cell Death Induction.
Zhao X; Zhang J; Chen B; Ding X; Zhao N; Xu FJ
Small Methods; 2023 May; 7(5):e2201595. PubMed ID: 36869418
[TBL] [Abstract][Full Text] [Related]
9. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
[TBL] [Abstract][Full Text] [Related]
11. Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-Mediated Tumor Immunotherapy.
Zhang Y; Li Q; Ding M; Xiu W; Shan J; Yuwen L; Yang D; Song X; Yang G; Su X; Mou Y; Teng Z; Dong H
Adv Healthc Mater; 2023 Jul; 12(17):e2203028. PubMed ID: 36807733
[TBL] [Abstract][Full Text] [Related]
12. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
13. Antigen Self-Presented Personalized Nanovaccines Boost the Immunotherapy of Highly Invasive and Metastatic Tumors.
Wang T; Han M; Han Y; Jiang Z; Zheng Q; Zhang H; Li Z
ACS Nano; 2024 Feb; 18(8):6333-6347. PubMed ID: 38349234
[TBL] [Abstract][Full Text] [Related]
14. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
[TBL] [Abstract][Full Text] [Related]
15. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
16. An Immunomodulatory Zinc-Alum/Ovalbumin Nanovaccine Boosts Cancer Metalloimmunotherapy Through Erythrocyte-Assisted Cascade Immune Activation.
Zhao J; Zhang L; Li P; Liu S; Yu S; Chen Z; Zhu M; Xie S; Ling D; Li F
Adv Sci (Weinh); 2024 Feb; 11(6):e2307389. PubMed ID: 38064201
[TBL] [Abstract][Full Text] [Related]
17. Regulating T-cell metabolic reprogramming and blocking PD-1 co-promote personalized postoperative autologous nanovaccines.
Chang L; Fu S; Gao T; Sang X; Yang H; Liu X; Yang H; Liu Y; Zhang N
Biomaterials; 2023 Jun; 297():122104. PubMed ID: 37058898
[TBL] [Abstract][Full Text] [Related]
18. Construction of pH-Sensitive Nanovaccines Encapsulating Tumor Cell Lysates and Immune Adjuvants for Breast Cancer Therapy.
Ding Y; Yang J; Wei H; Wang J; Huang S; Yang S; Guo Y; Li B; Shuai X
Small; 2023 Sep; 19(37):e2301420. PubMed ID: 37154213
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
[TBL] [Abstract][Full Text] [Related]
20. Nanovaccines: An effective therapeutic approach for cancer therapy.
Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
